ライフサイエンスコーパス: HIV-positive

1 nd non-TB respectively; 69.5% (105/151) were HIV positive.

2 n who have sex with men (MSM) or men who are HIV positive.

3 MSM aged 18-24 years tested in 2014, 3% were HIV positive.

4 SM aged 18-24 years tested in 2014, 26% were HIV positive.

5 tus established, of whom 11 964 (10.2%) were HIV positive.

6 olled 9812 participants, 3969 of whom tested HIV positive.

7 d to participate in the survey, and 141 were HIV positive.

8 uld want to start ART as soon as possible if HIV-positive.

9 Although 11 HIV-negative partners became HIV-positive (10 MSM; 1 heterosexual; 8 reported condoml

10 inically confirmed HIV were unaware of being HIV-positive (1768 [43%] of 4128 people in Zambia and 20

11 Of 293 (3%) children who were HIV positive, 220 (75%) registered for HIV care and 170

12 Of the remaining women who were HIV-positive, 93% were eligible for early ART (n = 148/1

13 ,927 (82.9%), including 2,569 ascertained as HIV-positive (942 tested HIV-positive and 1,627 reported

14 Although HIV-positive/active METH users have been shown to have h

15 this prospective international cohort study, HIV-positive adult participants (aged >/=16 years) from

16 dal risk among human immunodeficiency virus (HIV)-positive adults in Uganda.

17 cohort data of human immunodeficiency virus (HIV)-positive adults who started ART after 1995 within t

18 n common among human immunodeficiency virus (HIV)-positive adults, perhaps owing to persistent HIV-1

19 art of the SEARCH trial, 51% of east African HIV-positive adults had viral suppression, reflecting AR

20 art of the SEARCH trial, 51% of east African HIV-positive adults had viral suppression, reflecting AR

21 Regional viral suppression among HIV-positive adults occurred in 881 (48.2%) of 1827 peop

22 suppression occurred in 3427 (81.6%) of 4202 HIV-positive adults on ART and 4490 (50.9%) of 8828 HIV-

23 The estimated overall proportion of HIV-positive adults on ART, irrespective of whether they

24 Of 6,197 HIV-positive adults referred by CHiPs, 42% (95% CI: 40%-

25 this observational cohort study, we included HIV-positive adults registered between Jan 1, 2007, and

26 We included HIV-positive adults starting cART after 1 January 1996.

27 All HIV-positive adults were referred to the trial clinic in

28 s associated with an increased proportion of HIV-positive adults who achieved viral suppression, alon

29 We randomly assigned HIV-positive adults who had a CD4+ count of more than 50

30 tire population, the estimated proportion of HIV-positive adults who knew their status increased from

31 levels in CSF and plasma specimens from 220 HIV-positive adults who were taking suppressive ART.

32 his three-arm randomised controlled trial in HIV-positive adults with depression, we compared CBT-AD

33 tervention arm (immediate ART offered to all HIV-positive adults) and five clusters in the control ar

34 oniazid preventive therapy is recommended in HIV-positive adults, but subclinical tuberculosis can be

35 itive adults on ART and 4490 (50.9%) of 8828 HIV-positive adults.

36 At baseline, 13.4% of subjects were HIV positive and 15.1% were anemic.

37 tablished the proportion of all adults (both HIV positive and HIV negative) with a detectable viral l

38 ndomized trial of adults with cough who were HIV positive and/or at high risk of drug-resistant TB.

39 action between human immunodeficiency virus (HIV) positive and HIV-negative tuberculosis disease and

40 ,569 ascertained as HIV-positive (942 tested HIV-positive and 1,627 reported a known HIV-positive sta

41 oximately half of 40 tumor specimens from 23 HIV-positive and 17 HIV-negative patients (29 men and 11

42 Overall, 63% of women were HIV-positive and 49% had an uncircumcised male sex partn

43 immune-related genes was performed on select HIV-positive and HIV-negative cases in PD-L1+ tumor area

44 ping to reduce inequalities in HRQoL between HIV-positive and HIV-negative individuals in this genera

45 tudy differences in prevalence rates between HIV-positive and HIV-negative individuals.

46 in smokeless tobacco use prevalence between HIV-positive and HIV-negative men was not significant (1

47 elative falls in secondary syphilis for both HIV-positive and HIV-negative MSM nationally, suggesting

48 une microenvironment (TME) in anal SCCs from HIV-positive and HIV-negative patients.

49 comparable levels of IFNG in the TME of both HIV-positive and HIV-negative patients.

50 We aimed to compare HRQoL between HIV-positive and HIV-negative people in Zambia and South

51 al Transmission Study (VTS) supported EBF in HIV-positive and HIV-negative women; between 2012 and 20

52 gible if they were pregnant, had just tested HIV-positive and therefore could initiate antiretroviral

53 rtners tested for HIV, the number who tested HIV positive, and the number enrolled in HIV care, in th

54 These results indicate HIV-positive, antiretroviral therapy-naive South-African

55 A) and latex agglutination (LA) tests in 645 HIV-positive, ART-naive patients with CD4 counts </=100

56 Patients were included if HIV positive at KT, transplanted in the United Kingdom b

57 Women who had tested HIV positive at least 6 months prior, had initiated HIV

58 , and January, 2015, 470 participants tested HIV-positive at seven study primary health-care clinics

59 However, HIV-positive blacks continue to have much higher rates o

60 atment (30% vs. 20%; P = 0.12) was higher in HIV-positive cases compared with HIV-negative controls.

61 Rates of new HIV-positive cases identified through targeted testing i

62 bined strategy, the rate of newly identified HIV-positive cases identified through universal testing

63 Identification of new HIV-positive cases varied by strategy: 1 (0.1%) via univ

64 Many HIV-positive children in low-income and middle-income co

65 rovides an important opportunity to identify HIV-positive children.

66 HIV-associated nephropathy, 39 patients with HIV-positive CKD, and 39 patients with HIV-negative CKD)

67 positive/CMV-positive patients (795) than in HIV-positive/CMV-negative subjects (522, P = .006) or in

68 l counts were similar to controls' levels in HIV-positive/CMV-negative subjects.

69 re also found in coinfected patients than in HIV-positive/CMV-negative subjects.

70 Median CD8 counts/microL were higher in HIV-positive/CMV-positive patients (795) than in HIV-pos

71 nfluence of HLA class I on HBV in an African HIV-positive cohort.

72 stent warts, 42 noninfected controls, and 46 HIV-positive controls.

73 725 concordant HIV-negative couples and 209 HIV-positive couples enrolled in a male circumcision tri

74 man immunodeficiency virus (HIV)-negative or HIV-positive couples followed longitudinally.

75 rs in 60% of HIV-negative couples and 96% of HIV-positive couples over 2 years.

76 otype-specific concordance is more common in HIV-positive couples, and irrespective of HIV status, th

77 These associations were not seen in HIV-positive couples.

78 further research to understand the need for HIV-positive donors and the willingness of HIV-positive

79 IV-positive recipients to accept organs from HIV-positive donors is needed to inform future policy re

80 For potential HIV-positive donors, there are additional ethical challe

81 the management of patients, particularly for HIV-positive donors.

82 for HIV-negative FSWs and (2) early ART for HIV-positive FSWs.

83 and 41% (n = 110/270) of the women who were HIV-positive had CD4 counts within National Department o

84 CNS cryptococcal meningoencephalitis in both HIV positive (HIV+) and HIV negative (HIV-) subjects is

85 A cohort of 246 women [36.5% of whom were HIV positive (HIV+) and were receiving ART] were followe

86 levels in 229 varied autopsy tissues from 20 HIV-positive (HIV(+)) cART-treated study participants wi

87 preferentially targeted by ADCC mediated by HIV-positive (HIV(+)) sera.

88 Plasma samples from 20 HIV-positive (HIV(+)) subjects enrolled during primary H

89 of HIV-1-infected cells to ADCC mediated by HIV-positive (HIV+) sera.

90 solated resting, primary CD4(+) T cells from HIV-positive (HIV+) subjects on suppressive regimens wer

91 t in men who have sex with men (MSM) who are HIV-positive (HIV+).

92 Untreated HIV-positive (HIV-1(+)) individuals frequently suffer fr

93 The proportion of recents among HIV positives in the network of RS (27%) was approximate

94 dren with two or more samples, 223 (3%) were HIV positive (including five unconfirmed).

95 Intestinal microbiome changes that occur in HIV positive individuals on different antiretroviral the

96 understood in human immunodeficiency virus (HIV)-positive individuals.

97 was associated with a thinner media only in HIV-positive individuals (P = .01).

98 Overall, 635 (50%) of 1272 HIV-positive individuals achieved viral suppression at 9

99 Large arteries from 84 autopsied brains from HIV-positive individuals and 78 autopsied brains from HI

100 erpesviruses and the frequent coinfection of HIV-positive individuals by KSHV, we sought to determine

101 Additionally, HIV-positive individuals face adverse consequences beyon

102 After 2 years, 95.9% of HIV-positive individuals had been previously diagnosed (

103 mparison of cases versus controls with OSSN, HIV-positive individuals had larger (12 vs. 8 mm; P < 0.

104 in 2009, studies of the humoral responses of HIV-positive individuals have led to the identification

105 Among HIV-positive individuals in a large contemporary cohort,

106 dy, we used data from prospective studies of HIV-positive individuals in Europe (France, Greece, the

107 For HIV-positive individuals needing an organ transplant, is

108 Of the 1,177 HIV-positive individuals not previously in care and foll

109 , with approximately three-quarters of known HIV-positive individuals on ART by the end of the annual

110 The estimated proportion of known HIV-positive individuals on ART increased overall from 5

111 ing with HIV know their status, 90% of known HIV-positive individuals receive sustained antiretrovira

112 The life expectancy of HIV-positive individuals receiving antiretroviral therap

113 ight of updated WHO recommendations that all HIV-positive individuals should be treated with ART, reg

114 This target aims for 90% of HIV-positive individuals to be aware of their status, fo

115 hat 52% (95% credible intervals: 46%-58%) of HIV-positive individuals were aware of their status, 72%

116 All HIV-positive individuals were offered ART using a stream

117 cessarily in care (aware viral load), or all HIV-positive individuals whether they were aware, in car

118 m effect on rate of lung function decline in HIV-positive individuals who are naive to ART, with CD4

119 We hypothesized that HIV-positive individuals who do not develop TB, despite

120 itiation of ART in high-income countries for HIV-positive individuals who do not have AIDS: immediate

121 However, scores did differ between HIV-positive individuals who had initiated ART less than

122 tive individuals with HIV viral suppression, HIV-positive individuals who had received a diagnosis, d

123 In South Africa, HRQoL scores were lower in HIV-positive individuals who were aware of their status

124 ces in HRQoL scores between HIV-negative and HIV-positive individuals who were unaware of their statu

125 m HIV-positive living and deceased donors to HIV-positive individuals with end-stage organ disease in

126 The proportion of HIV-positive individuals with HIV viral suppression at b

127 To describe changes in the proportions of HIV-positive individuals with HIV viral suppression, HIV

128 need to be reduced by 4.34%, and ART use in HIV-positive individuals would need to increase by 19.5%

129 translating to 106,371 individuals or 52% of HIV-positive individuals).

130 With the improved longevity of HIV-positive individuals, a kidney transplant has become

131 ion (plasma HIV RNA<500 copies/mL) among all HIV-positive individuals, assessed at baseline and after

132 In HIV-positive individuals, MMP-9 was associated with doli

133 DS has set global targets to diagnose 90% of HIV-positive individuals, treat 90% of diagnosed individ

134 CD4 cell counts in virologically suppressed HIV-positive individuals.

135 spect to the optimal monitoring frequency of HIV-positive individuals.

136 w modalities for treating TB, especially for HIV-positive individuals.

137 deferred ART on decline in lung function in HIV-positive individuals.

138 e tested for HIV, with additional testing in HIV-positive individuals.

139 SHV DNA was detected in the CNS from 4 of 11 HIV-positive individuals.

140 developments in kidney transplantation among HIV-positive individuals.

141 immunological outcomes of virally suppressed HIV-positive individuals.

142 who receive test results and the linkage of HIV-positive infants to antiretroviral therapy with the

143 South Africa, unprecedented HIV-positive-to-HIV-positive liver transplantations and living-donor kid

144 ct now allows transplantation of organs from HIV-positive living and deceased donors to HIV-positive

145 reatment among human immunodeficiency virus (HIV)-positive men who have sex with men (MSM) between 20

146 epidemic among human immunodeficiency virus (HIV)-positive men who have sex with men (MSM) in the Uni

147 e women, 56% of HIV-negative men, and 93% of HIV-positive men and women.

148 , smokeless, and any tobacco use) among 6729 HIV-positive men from 27 LMICs (aged 15-59 years) and 11

149 ctivation were measured in stored serum from HIV-positive men obtained after cART-induced HIV suppres

150 We found a higher prevalence in HIV-positive men of any tobacco use (risk ratio [RR] 1.4

151 Screening HIV-positive men or MSM for syphilis every 3 months is a

152 nths vs 6 or 12 months for early syphilis in HIV-positive men or MSM.

153 The overall prevalence among HIV-positive men was 24.4% (95% CI 21.1-27.8) for tobacc

154 HIV-positive men were randomised to a single subcutaneou

155 For HIV-positive men who have sex with men, our estimates su

156 ion between transmitting and nontransmitting HIV-positive mothers have been correlated with transmiss

157 results support current recommendations that HIV-positive mothers in resource-limited settings exclus

158 ramatically in mothers versus children, with HIV-positive mothers shedding at a higher rate than HIV-

159 n for HGAIN in human immunodeficiency virus (HIV)-positive MSM aged >/=27 years.

160 ss receptive anal intercourse (CRAI) with an HIV-positive MSM (3 points), the combination of CRAI plu

161 IV-negative (48% to 91%; Ptrend < .0001) and HIV-positive MSM (42% to 77%; Ptrend < .0001).

162 MSM (Ptrend < .0001) and from 1.6 to 2.3 in HIV-positive MSM (Ptrend < .0001).

163 Vaccinating HIV-positive MSM aged >/=27 years with qHPV vaccine afte

164 ed a Markov model based on anal histology in HIV-positive MSM comparing qHPV vaccination with no vacc

165 35% (531 of 1505) of HIV-positive MSM had undiagnosed infection, which decrea

166 HCV prevalence among HIV-positive MSM in UK CHIC increased from 7.3% in 2004

167 ered were offering HPV vaccination to either HIV-positive MSM or MSM regardless of HIV status, for ag

168 Offering vaccination to HIV-positive MSM up to age 40 is likely to be cost-effec

169 ths of this study are the high proportion of HIV-positive MSM with a sequence in this study and the c

170 Among HIV-positive MSM, decreasing secondary syphilis correlat

171 Among HIV-positive MSM, early latent infections increased from

172 ilis cases were detected in HIV-negative and HIV-positive MSM, respectively.

173 2339 (15%) participants tested HIV positive, of whom 1325 (57%) were randomly assigned

174 therapy with isoniazid preventive therapy in HIV-positive outpatients initiating antiretroviral thera

175 , compared with eight (18%) of 45 who tested HIV-positive (p<0.0001); condoms were used in all eight

176 to account the perspectives of at least 2263 HIV-positive participants (740 men, 1008 women, 78 trans

177 Eligible HIV-positive participants (aged >/=16 years) were random

178 12 clusters (58 cluster-years) and referred HIV-positive participants to trial clinics for ART (fixe

179 1218 (93%) of 1303 HIV-positive participants were linked to care, but only

180 24); 90% and 77%, respectively, for the 115 HIV-positive participants with culture-positive sputum (

181 Two PoC assays were evaluated in 40 HIV-positive participants, 20 with detectable and 20 wit

182 Of 1,257 (11.8%) HIV-positive participants, 26.0% were already on antiret

183 and enrolled 1166 HIV serodifferent couples (HIV-positive partner taking suppressive ART) who reporte

184 Condomless sexual activity with an HIV-positive partner taking virally suppressive ART.

185 nt heterosexual and MSM couples in which the HIV-positive partner was using suppressive ART and who r

186 ordant: in 445 (53.0%) of these couples, the HIV-positive partner was viraemic (and in 129 [15%], vir

187 ordant: in 287 (58.3%) of these couples, the HIV-positive partner was viraemic (and in 69 [14.0%], vi

188 cordant couples, measuring the proportion of HIV-positive partners with detectable viraemia.

189 ported at least one injury while treating an HIV-positive patient, and 626 (71%) of 884 reported prio

190 Median age of HIV positive patients enrolled was 13 years (interquarti

191 viro-immunological controlled HAART treated HIV positive patients was efficacious, safe and well tol

192 nfirmation at diagnosis in a large cohort of HIV positive patients.

193 hms for use in human immunodeficiency virus (HIV)-positive patients are urgently needed.

194 tation (KT) of human immunodeficiency virus (HIV)-positive patients has transformed the management of

195 restoration in human immunodeficiency virus (HIV)-positive patients is dependent on thymic function.

196 uent cancer in human immunodeficiency virus (HIV)-positive patients starting combination antiretrovir

197 splantation in human immunodeficiency virus (HIV)-positive patients who receive organs from HIV-negat

198 Consecutive HIV-positive patients aged 16 years or older with a diag

199 ed medical data sets with a cohort of 21,207 HIV-positive patients and 5,298,496 controls stratified

200 ession and may reflect history of disease in HIV-positive patients and adolescents.

201 ate an immune-reactive TME in anal SCCs from HIV-positive patients and support clinical investigation

202 specimens obtained from 12 actively smoking HIV-positive patients before ART initiation and after AR

203 Cutaneous wart biopsy specimens from HIV-positive patients harbored common wart types HPV27/5

204 en successfully rolled out at large scale to HIV-positive patients in low-income and middle-income co

205 mononuclear cells to exosomes purified from HIV-positive patients induced CD38 expression on naive a

206 dence of AR in the first year after KT in 78 HIV-positive patients of whom 31 initiated cyclosporin (

207 ategies for mitigating risk and treatment of HIV-positive patients presenting with CHD.

208 ure-negative PTB (82.4%) and EPTB (75.0%) in HIV-positive patients significantly outperformed those r

209 prevalence of tuberculosis among Mozambican HIV-positive patients starting antiretroviral therapy wa

210 ngitudinal prospective study, we followed 69 HIV-positive patients who were perinatally infected.

211 s a randomised controlled trial in ART-naive HIV-positive patients with CD4 cell count of more than 5

212 option with minimal adverse effects for most HIV-positive patients with genotype 1 HCV.

213 analyzed in 49 antiretroviral (ART)-treated HIV-positive patients with persistent warts, 42 noninfec

214 e HLA-B*44 was more frequently identified in HIV-positive patients with warts (P = .004); a susceptib

215 ty of tuberculosis cases, particularly among HIV-positive patients, including patients receiving ART.

216 2/EY-0.35/EY) among the HIV-negative and the HIV-positive patients, respectively.

217 tegy offers promise of enhanced outcomes for HIV-positive patients.

218 ble as a biomarker of active tuberculosis in HIV-positive patients.

219 group of grass pollen-allergic HAART-treated HIV-positive patients.

220 HPV types associated with cutaneous warts in HIV-positive patients.

221 ation and subsequent cognitive impairment in HIV-positive patients.

222 lation with disease progression over time in HIV-positive patients.

223 and high-dose cytarabine (CODOX-M/IVAC) for HIV-positive patients.

224 ns among HIV-negative patients but not among HIV-positive patients.

225 treatments for human immunodeficiency virus (HIV)-positive people who inject drugs (PWID) are unclear

226 However, only about half of HIV-positive people accessed care within 6 mo of being i

227 ure strategies to increase the proportion of HIV-positive people accessing treatment and achieving vi

228 Of 4685 HIV-positive people enrolled, 120 had severe bacterial i

229 Deaths in HIV-positive people have decreased since the introductio

230 non-suppression, and virological rebound, in HIV-positive people on ART in the UK.

231 tive people, and mortality remains higher in HIV-positive people than in the general population.

232 tive people, and mortality remains higher in HIV-positive people than in the general population.

233 strategies achieved high rates of linkage of HIV-positive people to HIV clinics, roughly a third of w

234 Primary outcomes for HIV-positive people were obtaining a CD4 cell count, lin

235 ART) almost eliminates HIV transmission from HIV-positive people who are virally suppressed; however,

236 irus (HIV)-AIDS strategies, its effect among HIV-positive people who use illicit drugs (PWUD) has yet

237 sk of several severe bacterial infections in HIV-positive people with high CD4 cell count.

238 ues to account for the majority of deaths in HIV-positive people, and mortality remains higher in HIV

239 ues to account for the majority of deaths in HIV-positive people, and mortality remains higher in HIV

240 y observed level of 36% viral suppression in HIV-positive people, HIV incidence decreases by 33.8% ov

241 rate [eGFR] </= 60 ml/min/1.73 m2) events in HIV-positive people.

242 dressing modifiable risks for CVD and CKD in HIV-positive people.

243 The prevalence of ocular complications in HIV positive persons under treatment in Ghana is high.

244 s of retesting human immunodeficiency virus (HIV)-positive persons before antiretroviral therapy (ART

245 sing number of human immunodeficiency virus (HIV)-positive persons seeking organ transplantation and

246 onor kidney transplants from HIV-positive to HIV-positive persons in South Africa, unprecedented HIV-

247 HIV viral-load suppression among all HIV-positive persons increased from 42% in 2009 to 75% b

248 ty MMC coverage in males and ART coverage in HIV-positive persons of the opposite sex based on self-r

249 This suggests that CVD and CKD risk in HIV-positive persons should be assessed together.

250 for a population-level target of 73% of all HIV-positive persons with HIV viral suppression.

251 have sex with men, persons who inject drugs, HIV-positive persons, household and sexual contacts of H

252 an immunodeficiency virus (HIV)-negative and HIV-positive persons, respectively.

253 l treatment (ART) is now recommended for all HIV-positive persons.

254 mains an important comorbid condition in the HIV-positive population and an emerging concern among HI

255 Cohort data were also added from HIV-positive populations in Malawi and Ghana.

256 subjects (31% human immunodeficiency virus [HIV] positive) pre- and post-DAA therapy (median follow-

257 91% of HIV-positive pregnant women reside in sub-Saharan Africa

258 ival Services study, a prospective cohort of HIV-positive PWUD linked to HIV clinical monitoring reco

259 inued efforts to scale up ART coverage among HIV-positive PWUD.

260 r HIV-positive donors and the willingness of HIV-positive recipients to accept organs from HIV-positi

261 nsplantation and serving as organ donors for HIV-positive recipients, HHV-8 prevalence among donors a

262 gion was sequenced and characterized for 172 HIV-positive specimens.

263 education, HIV testing history, awareness of HIV positive status, and higher community antiretroviral

264 Among men, partner's HIV-positive status (adjusted hazard ratio [aHR] 2.67, 1

265 Knowledge of HIV-positive status increased steeply after 1 y, almost

266 sted HIV-positive and 1,627 reported a known HIV-positive status).

267 n 40 years, 62 (78.5%) were unaware of their HIV-positive status, 76 (96.2%) were not on antiretrovir

268 rier to HIV care engagement was awareness of HIV-positive status.

269 s proviral DNA levels in CD4(+) T cells from HIV-positive subjects on suppressive ART, an effect that

270 point-of-care CD4+ testing at the time of an HIV-positive test, accelerated antiretroviral therapy (A

271 th plus retention in care at 12 months after HIV-positive testing.

272 er of deceased-donor kidney transplants from HIV-positive to HIV-positive persons in South Africa, un

273 itive persons in South Africa, unprecedented HIV-positive-to-HIV-positive liver transplantations and

274 Initially, all HIV-positive-to-HIV-positive transplantations will occur

275 Initially, all HIV-positive-to-HIV-positive transplantations will occur under research

276 ociation study of TB resistance by using 581 HIV-positive Ugandans and Tanzanians enrolled in prospec

277 o cultures of resting CD4(+) T cells from 14 HIV-positive volunteers revealed that virion production

278 d gene expression profiles in anal SCCs from HIV-positive vs HIV-negative patients.

279 Twenty patients who were HIV positive were recruited from adult outpatient clinic

280 2,197 adults aged >/=18 years, newly tested HIV positive, were enrolled from 19 August 2013 to 21 No

281 in children older than 12 months or who were HIV positive, which is consistent with comorbidity and e

282 tinue to have much higher rates of ESRD than HIV-positive whites, which could be attributed to the AP

283 ered livebirths at RMMCH and 4267 (23%) were HIV-positive with 4336 HIV-exposed neonates delivered.

284 876 eligible MSM recruited, 1512 (13%) were HIV positive, with no significant trend in HIV positivit

285 s discuss viral load monitoring for pregnant HIV-positive women and those breastfeeding; ART treatmen

286 al cancer screening should be considered for HIV-positive women as part of their routine care.

287 us in breast milk, most infants breastfed by HIV-positive women do not acquire HIV.

288 from 27 LMICs (aged 15-59 years) and 11 495 HIV-positive women from 28 LMICs (aged 15-49 years), and

289 ypes, including HPV-16, in the anal canal of HIV-positive women is concerning.

290 trol studies reporting perinatal outcomes in HIV-positive women naive to antiretroviral therapy and H

291 We found a higher prevalence in HIV-positive women of any tobacco use (RR 1.36 [95% CI 1

292 ntraception on time to HIV transmission from HIV-positive women to their HIV-negative male partners (

293 The overall prevalence among HIV-positive women was 1.3% (95% CI 0.8-1.9) for tobacco

294 of high-risk HPV-type distribution in 19883 HIV-positive women was performed.

295 HPV genotyping tests also have relevance for HIV-positive women.

296 tested, proportion of previously undiagnosed HIV-positive youths identified, and rates of linkage to

297 A total of 3986 HIV-positive youths were referred for care, with more th

298 f color), identifying previously undiagnosed HIV-positive youths, and linking HIV-negative youths to

299 vous system (CNS) can be infected by KSHV in HIV-positive Zambian individuals.

300 an CNS-resident cells, primarily neurons, in HIV-positive Zambian individuals.